Servier Deutschland GmbH

Company

    • Company type:
      • Distributor
      • Research & Development
    • Year founded:
    • 1954
    • Employees (at the site):
    • 437
    • Turnover range:
    • 5m - <10m EUR
    • Products/services:
    • Since its foundation in 1954, SERVIER has launched 40 innovative drugs from its own research. Currently, there are 9 drugs distributed by SERVIER Deutschland.

      The focus of SERVIER Deutschland is the treatment of cardiovascular diseases, hypertension, osteoporosis and depression.

      SERVIER worldwide is currently distributing 22 innovative drugs and has a range of products for the following indications:

      - Hypertension
      - Heart failure
      - Angina pectoris
      - Venous insufficiency
      - Diabetes
      - Hyperlipidemia
      - Asthenie
      - Depression
      - Cerebral circulatory disorder
      - Infection and inflammation upper respiratory tract
      - Chronic-obstructive respiratory disease
      - Malignant melanoma
      - Osteoporosis

    • Core competencies:
    • - Research and development
      - Clinical development of our pharmaceutical drugs within the German-speaking area
      - Marketing and sales specifically in the indications of cardiovascular diseases (CV), diseases of the central nervous system (CNS) and osteoporosis

    • Language skills:
    • English
      French
      German
    • Key Tech / section:
      • Biotechnology: Biomaterials
      • Biotechnology: Therapeutic drug development
      • Biotechnology: Tissue engineering and regenerative medicine
      • Chemical Industry: Pharmaceutical basic products
      • Medical Technology: Implants, biomaterials, tissue engineering
    • Industries NACE:
      • 72: Scientific research and development
      • 21: Manufacture of basic pharmaceutical products and pharmaceutical preparations
    • Certification:
    • not available

    • Sales markets - target industries:
    • Ärzte und Apotheker in den Indikationsgruppen CV, ZNS, Osteoporose
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Oliver Kirst (Mr.)
      - Management